Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

New and Highly Efficient Therapy for Treatment NPM-ALK Associated Lymphomas

Lukas Kenner, Daniela Laimer, Helmut Dolznig, Paul Vesely, Karoline Kollmann, Ana-Iris Iris Schiefer, Veronika Sexl, MD, Philipp B Staber, M.D., Gerald Hoefler, Josef Penninger, Giorgio Inghirami, Jaeger Ulrich

Blood (2011) 118 (21): 1659.

https://doi.org/10.1182/blood.V118.21.1659.1659

Published: 2011

Journal Articles

Identification of Critical Phosporylation Sites within NPM-ALK That Regulate JUNB mRNA Translation.

Claudia Fuchs, Paul Vesely, Ms, Isabella Bambach, Silvia Schauer, Werner Linkesch, MD, David W. Sternberg, MD, PhD, Gerald Hoefler, MD, Philipp B. Staber, MD

Blood (2007) 110 (11): 3571.

https://doi.org/10.1182/blood.V110.11.3571.3571

Published: 2007

Journal Articles

The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling

Philipp B. Staber, Paul Vesely, Naznin Haq, Rene G. Ott, Kotaro Funato, Isabella Bambach, Claudia Fuchs, Silvia Schauer, Werner Linkesch, Andelko Hrzenjak, Wilhelm G. Dirks, Veronika Sexl, Helmut Bergler, Marshall E. Kadin, David W. Sternberg, Lukas Kenner, Gerald Hoefler

Blood (2007) 110 (9): 3374–3383.

https://doi.org/10.1182/blood-2007-02-071258

Published: 2007

Includes: Supplemental data

Journal Articles

NPM-ALK Converts JUNB from a Tumor Suppressor to an Oncogene.

Paul Vesely, MS, Philipp B. Staber, MD, Rene Ott, PhD, Montserrat Pinent, PhD, Werner Linkesch, MD, Silvia Schauer, Andelko Hrzenjak, PhD, Marshall E. Kadin, MD, David W. Sternberg, MD PhD, Gerald Hoefler, MD

Blood (2006) 108 (11): 1448.

https://doi.org/10.1182/blood.V108.11.1448.1448

Published: 2006

Journal Articles

NPM-ALK Fusion Tyrosine Kinase of Anaplastic Large Cell Lymphoma Exerts Its Transforming Potential by Increasing Translation of JUNB through mTOR and S6K1.

Philipp B. Staber, MD, Paul Vesely, MS, Rene Ott, PhD, Naznin Haq, Werner Linkesch, MD, Silvia Schauer, Andelko Hrzenjak, PhD, Lukas Kenner, MD, Wilhelm Dirks, PhD, Marshall E. Kadin, MD, David W. Sternberg, MD PhD, Gerald Hoefler, MD

Blood (2006) 108 (11): 1428.

https://doi.org/10.1182/blood.V108.11.1428.1428

Published: 2006

NARROW

New and Highly Efficient Therapy for Treatment NPM-ALK Associated Lymphomas

Identification of Critical Phosporylation Sites within NPM-ALK That Regulate JUNB mRNA Translation.

The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling

NPM-ALK Converts JUNB from a Tumor Suppressor to an Oncogene.

NPM-ALK Fusion Tyrosine Kinase of Anaplastic Large Cell Lymphoma Exerts Its Transforming Potential by Increasing Translation of JUNB through mTOR and S6K1.

Email alerts

ASH Publications

American Society of Hematology

New and Highly Efficient Therapy for Treatment NPM-ALK Associated Lymphomas

Identification of Critical Phosporylation Sites within NPM-ALK That Regulate JUNB mRNA Translation.

The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling

NPM-ALK Converts JUNB from a Tumor Suppressor to an Oncogene.

NPM-ALK Fusion Tyrosine Kinase of Anaplastic Large Cell Lymphoma Exerts Its Transforming Potential by Increasing Translation of JUNB through mTOR and S6K1.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only